Utah recently became the first state to allow AI chatbots to refill psychiatric prescriptions.
The western state is currently experiencing one of the highest physician shortages, according to United Health Foundation’s America’s Health Ranking. In order to address access barriers and extended wait times, Utah health officials authorized agentic AI chatbots to independently refill prescriptions for psychiatric drugs, including SSRIs and anti-anxiety medications. Doctronic AI, a platform that offers digital clinicians and doctors with decision-making capabilities, is piloting the new program.
The pilot program comes as the federal government ramps up TrumpRX, a national initiative aimed at slashing the cost of name-brand psychiatric drugs. Several brand-name medications cleared for AI-driven refills are included in the TrumpRx program.
“Health care has become too complex and expensive for Utah families,” said Utah Senator Kirk Cullimore in a statement. “Utah is leading efforts to simplify costs and lower prescription drug prices through our ‘regulatory sandbox,’ which fosters innovation and helps patients get the medications they need while reducing costs and building trust in the process.”
This new directive is an expansion of the initial program, which officials launched in January. It allows AI agents to renew 191 medications for chronic diseases. Senator Cullimore added that the new partnership isn’t meant to replace doctors, but enhance patient experience.
“This partnership with Doctronic reinforces the principle of ‘doctor, not device,’ ensuring automation supports, rather than replaces, human judgment as we lead the nation in responsible healthcare policy,” he said.
Inside Utah’s Algorithmic Safety Net
This first-of-its-kind program was made possible by the Utah Artificial Intelligence Policy Act. This unique law temporarily relieves regulations and licensing requirements to facilitate AI innovations in healthcare.
“Utah’s approach to regulatory mitigation strikes a vital balance between fostering innovation and ensuring consumer safety,” said Margaret Woolley Busse, executive director of the Utah Department of Commerce. “By creating a supportive environment for companies like Doctronic AI, the Utah Office of Artificial Intelligence Policy provides the certainty necessary for them to develop impactful solutions while prioritizing the well-being of Utahns.”
Under the authorization, Doctronic’s can process renewals of up to 90 days for medications already prescribed by licensed providers. The platform is prohibited from writing new prescriptions or renewing controlled substances.
The state limited the platform’s formulary to maintenance medications. The program authorizes refills for chronic and mental health conditions, including PTSD, depression, anxiety, and smoking cessation.
According to Utah officials, strict guardrails and privacy protocols are in place. Human physicians must review the agentic AI’s decision for the first 250 patients. They must also review the next 1,000 cases to ensure a 98% accuracy rate. The platform has a built-in escalation process that refers complex cases to clinicians.
Critics Eye Utah’s Agentic AI Experiment
The Regulatory Mitigation Agreement between Utah and Doctronic relies on self-reporting and office review. Doctronic is required to report safety incidents within 24 hours, but the initial deployment phase does not require independent evaluation.
In an article published by JAMA Health Forum, Stanford Professor Michelle Mello said automated prescription renewal programs could lead to “collateral harms.” Mello cited that reducing doctor-patient interactions with AI could be the cause of the harm.
“Physicians often use prescription expirations as an opportunity for clinical touch points that yield other benefits” Mello said. “The Doctronic system offers patients an alternative that could result in collateral harms.”
Still, Mello said the program deserves careful consideration rather than outright rejection. For now, Utah officials are betting that a regulated use of artificial intelligence can help address the state’s clinician shortage.
However, important questions remain on how the program is impacting outcomes. The office said it does not yet have strong evidence of benefits. Outcome measures are scheduled for later phases, after safety is more fully established.
